S H Thorne
Affiliation: University of Pittsburgh
- Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virusSteve H Thorne
Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
Expert Opin Biol Ther 4:1307-21. 2004....
- Design and testing of novel oncolytic vaccinia strainsSteve H Thorne
Division of Surgical Oncology, University of Pittsburgh, PA, USA
Methods Mol Biol 542:635-47. 2009....
- Importance of glycolysis and oxidative phosphorylation in advanced melanomaJonhan Ho
Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA
Mol Cancer 11:76. 2012....
- The role of GM-CSF in enhancing immunotherapy of cancerSteve H Thorne
University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e HCC, 5117 Center Avenue, Pittsburgh, PA 15238, USA
Immunotherapy 5:817-9. 2013....
- Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killingYoram Barak
Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA
BMC Cancer 10:146. 2010..Whether NO generation by the bacteria has a role in SL7838 lethality to cancer cells is explored. This bacterium has the mechanism for generating NO, but also for decomposing it...
- Oncolytic vaccinia virus: from bedside to benchtop and backSteve H Thorne
University of Pittsburgh Cancer Institute and Division of Surgical Oncology, Hillman Cancer Center, 5150 Centre Avenue, University of Pittsburgh, Pittsburgh, PA 15232, USA
Curr Opin Mol Ther 10:387-92. 2008..Preclinical models incorporating new oncolytic vaccinia strains, as well as data from the first clinical trials that have utilized the next-generation oncolytic vaccinia strains for the potential treatment of cancer have been described...
- Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based deliveryS H Thorne
University of Pittsburgh Cancer Institute, Department of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
Gene Ther 15:753-8. 2008..Similarly, if we are to develop targeted therapies that are sufficiently multifaceted to eliminate cancer cells at all stages of disease, we should integrate the virus into the unique biology of the cell delivery vehicle...
- Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapyStephen H Thorne
University of Pittsburgh Cancer Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15238, USA
Mol Ther 18:1698-705. 2010..This therefore represents a novel and effective means to overcome localized immune suppression within the tumor microenvironment...
- Immunotherapeutic potential of oncolytic vaccinia virusSteve H Thorne
Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Immunol Res 50:286-93. 2011..Approaches to developing next-generation vectors that are capable of effectively harnessing both of these mechanisms of action are discussed here...
- Next-generation oncolytic vaccinia vectorsSteve H Thorne
Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
Methods Mol Biol 797:205-15. 2012....
- Enhancing biological therapy through conditional regulation of protein stabilitySteve H Thorne
Departments of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
Expert Rev Mol Med 12:e2. 2010....
- Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1B Huang
Departments of Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15238, USA
Gene Ther 18:164-72. 2011..These data may provide a direct basis for the design of clinical trials with agents currently in the clinic, as well as providing insight into the development of next generation viral vectors...
- Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virusDavid H Kirn
Jennerex Biotherapeutics, San Francisco, California, United States of America
PLoS Med 4:e353. 2007..We report the construction and preclinical testing of this virus...
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Steve H Thorne
Department of Pediatrics and Bio X Program, James H Clark Center, Stanford University School of Medicine, Stanford, California, USA
J Clin Invest 117:3350-8. 2007..JX-963 therefore holds promise as a rationally designed, targeted virotherapeutic for the systemic treatment of cancer in humans and warrants clinical testing...
- Strategies to achieve systemic delivery of therapeutic cells and microbes to tumorsSteve H Thorne
Stanford University, Bio X Programme and Department of Pediatrics, Clark Center, California 94305, USA
Expert Opin Biol Ther 7:41-51. 2007....
- Synergistic antitumor effects of immune cell-viral biotherapySteve H Thorne
Departments of Pediatrics, Radiology, Microbiology, and Immunology Stanford University School of Medicine, Stanford, CA 94305, USA
Science 311:1780-4. 2006..These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer...
- Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical studyJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
Clin Cancer Res 12:1859-67. 2006..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
- Enhancing Delivery and Regulating Gene Expression in Oncolytic Vaccinia VectorsStephen H Thorne; Fiscal Year: 2010....